Morgan Stanley Evelo Biosciences, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.17 - $1.57 $3,447 - $31,839	-20,280 Reduced 25.71%	58,612 $10,000
Q4 2022 Feb 14, 2023	BUY	$1.44 - $48.2 $20,976 - $702,129	14,567 Added 22.65%	78,892 $127,000
Q3 2022 Nov 14, 2022	SELL	$1.86 - $41.8 $139,942 - $3.14 Million	-75,238 Reduced 53.91%	64,325 $134,000
Q2 2022 Oct 27, 2022	BUY	$1.46 - $3.55 $130,332 - $316,904	89,269 Added 177.49%	139,563 $294,000
Q2 2022 Aug 15, 2022	BUY	$1.46 - $3.55 $130,332 - $316,904	89,269 Added 177.49%	139,563 $294,000
Q1 2022 Oct 27, 2022	SELL	$2.66 - $6.63 $237,455 - $591,853	-89,269 Reduced 63.96%	50,294 $171,000
Q1 2022 May 13, 2022	SELL	$2.66 - $6.63 $377 - $941	-142 Reduced 0.28%	50,294 $171,000
Q4 2021 Feb 14, 2022	SELL	$6.07 - $12.0 $180,327 - $356,496	-29,708 Reduced 37.07%	50,436 $306,000
Q3 2021 Nov 15, 2021	BUY	$6.79 - $13.9 $544,177 - $1.11 Million	80,144 New	80,144 $564,000

Ticker EVLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,994,000
Description
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hy...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.